

Alternative Payment Models to Promote Collaboration and Value in Cancer Diagnosis and Treatment

Stephen S. Grubbs, MD, FASCO

Vice President Clinical Affairs

American Society of Clinical Oncology

February 12, 2018

No disclosures

Volume to Value Payment Reform

- Value Based Payment promotes care quality and value with payment more closely related to outcome
- CMS mandating a move from fee for service to value based payment system
- Alternative Payment Models (APM's) reward providers for delivering high quality, cost efficient care



"...moving away from the old way of doing things, which amounted to 'the more you do, the more you get paid.'"

Sylvia M. Burwell
HHS Secretary
2014-2017

Health Care Payment Learning and Action Network (HCP-LAN)


Modified CMS Payment Categories



HCP-LAN 2017

2019 CMS QUALITY PAYMENT PROGRAM (QPP)

Merit Based Incentive
Payment System



Alternative
Payment
Models

Center for Medicare and Medicaid Innovation (CMMI): Oncology Care Model (OCM)

- 5 year voluntary pilot project initiated in July, 2016
- Goal: Improve quality of care and lower Medicare spending
- Approximately 190 participating practices in 31 states
- Model features
 - Utilization of acceptable treatments based on guidelines
 - Report implemented care improvement and outcomes and use data for continuous quality improvement

Oncology Clinical Pathways

Definition of a clinical pathway

- An oncology clinical pathway is a **detailed protocol for delivering cancer care**, including but not limited to anticancer drug regimens, for specific patient populations, including the type, stage, and molecular subtype of disease.
- Whereas guidelines offer multiple recommendations, **clinical pathways “translate guidelines or evidence into local structure”** and aim to delineate the best treatments often inclusive of dosing, time frames, and sequencing of therapies
- A clinical pathway’s objective is to **facilitate quality care in all aspects of the patient interaction** to include evaluation (diagnostics), treatment, surveillance, supportive care, and end-of-life care


Source: Rotter T, Kinsman L, James E, Machotta A, Steyerberg EW. The quality of the evidence base for clinical pathway effectiveness: room for improvement in the design of evaluation trials. *BMC medical research methodology*. Jun 18 2012;12:80; Lawal AK, Rotter T, Kinsman L, et al. What is a clinical pathway? Refinement of an operational definition to identify clinical pathway studies for a Cochrane systematic review. *BMC medicine*. Feb 23 2016;14:35;

The Growth of Oncology Clinical Pathways

Trends in cancer care delivery – Oncology clinical pathways

- ASCO's *The State of Cancer Care in America, 2017*, documents a 42% increase in the percentage of practices reporting compliance with a clinical pathways program

Percent of Practices Reporting Compliance with a Clinical Pathway Program (ASCO)



Source: The State of Cancer Care in America, 2017: A Report by the American Society of Clinical Oncology. *J Oncol Pract* 13:e353-e394,2017.

Criteria for High-Quality Clinical Pathways

Criteria for High-Quality Clinical Pathways in Oncology

Pathway Development

- Expert driven
- Reflects stakeholder input
- Transparent
- Evidence-based
- Patient-focused
- Clinically-driven
- Up-to-Date
- Comprehensive
- Promotes participation in clinical trials

Implementation & Use

- Clear and achievable expected outcomes
- Integrated, cost-effective technology and decision support
- Efficient processes for communication and adjudication

Analytics

- Efficient and public reporting of performance metrics
- Outcomes-driven results
- Promotes research and continuous quality improvement

Source: Zon RT, Edge SB, Page RD, et al. American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology; *J Oncol Pract.* 2017 Mar;13(3):207-210.

ASCO Patient Centered Oncology Payment Model

- **Adherence to Clinical Pathways** (diagnostic, treatment, triage, survivorship) is a quality metric
- Additional quality metrics from Quality Oncology Practice Initiative (QOPI) 180 measures and Choosing Wisely
- Reduces unwarranted variation in diagnostics and treatment, which decreases cost and enhances quality
- Protects against underutilization
- Allows patient and physician autonomy (personalized care)



www.asco.org/paymentreform

ASCO[®]

Performance Measures for High Value, High Quality Cancer Care

- Compliance with evidence based clinical pathways
 - Laboratory and imaging testing
 - Appropriate use of drugs including less costly equivalents
- Triage Pathway utilization to eliminate avoidable emergency room and hospital use
- Follow post therapy pathways for evidence based survivorship monitoring and end of life care
- Care consistent with standards of quality (ASCO QOPI)

Evidence Based Clinical Pathway Utilization in Value Based Payment Models (APM) Ensure High Quality Care

- Compliance with correct and appropriate diagnostics
- Standardize therapy while maintaining patient/physician autonomy
- Guide therapeutic adjustments
- Accelerate toxicity diagnosis and intervention
- Rapidly disseminate and adopt new technology and therapeutics
- Encourage clinical trial participation
- Guide appropriate survivorship care and monitoring
- Eliminate care disparities and safe guards patients from under utilization

Take Home Messages

- **The transition from volume based to value based payment models (Alternative Payment Models) offers the opportunity to improve practice compliance with high quality cancer diagnostics, treatments, and patient monitoring.**
- **Utilization and compliance with high quality value pathways help ensure appropriate diagnostics, therapeutics, and patient monitoring resulting in improved quality of care, rapid adoption of new knowledge, and elimination of disparity.**

Thank You